KPTI (STOCKS)
Karyopharm Therapeutics Inc.
$1.970000
-0.060000 (-2.96%)
Prev close: $2.030000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- CEO
- Richard A. Paulson
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $46.47M
- Employees
- 279
- P/E (TTM)
- -0.13
- P/B (TTM)
- -0.17
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
3
Strong Buy
6
Buy
3
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Jun 2026 (Q2)
|
$-2.32 | $-1.30 | -1.0178 | -78.16% |
|
Mar 2026 (Q1)
|
$-1.02 | $-1.46 | +0.4371 | +30.00% |
|
Dec 2025 (Q4)
|
$-2.22 | $-2.03 | -0.1858 | -9.13% |
|
Sep 2025 (Q3)
|
$-3.82 | $-3.19 | -0.6269 | -19.63% |
Financial Statements
| Revenues | $151.12M |
| Benefits Costs and Expenses | $346.08M |
| Costs And Expenses | $346.08M |
| Nonoperating Income/Loss | -$110.75M |
| Operating Expenses | $235.33M |
| Selling, General, and Administrative Expenses | $104.54M |
| Research and Development | $124.80M |
| Other Operating Expenses | $5.99M |
| Operating Income/Loss | -$84.21M |
| Income/Loss From Continuing Operations After Tax | -$194.97M |
| Income/Loss From Continuing Operations Before Tax | -$194.96M |
| Income Tax Expense/Benefit | $8.00K |
| Net Income/Loss | -$194.97M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$194.97M |
| Net Income/Loss Available To Common Stockholders, Basic | -$194.97M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$16.16 |
| Diluted Earnings Per Share | -$16.38 |
| Basic Average Shares | 41,651 |
| Diluted Average Shares | 44,352 |
| Assets | $131.42M |
| Current Assets | $126.33M |
| Cash | $90.90M |
| Accounts Receivable | $23.36M |
| Inventory | $3.60M |
| Other Current Assets | $8.48M |
| Noncurrent Assets | $5.08M |
| Fixed Assets | $91.00K |
| Other Non-current Assets | $4.99M |
| Liabilities | $397.06M |
| Current Liabilities | $117.30M |
| Accounts Payable | $4.28M |
| Other Current Liabilities | $113.02M |
| Noncurrent Liabilities | $279.76M |
| Equity | -$265.65M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | -$265.65M |
| Liabilities And Equity | $131.42M |
| Net Cash Flow From Operating Activities | -$59.11M |
| Net Cash Flow From Operating Activities, Continuing | -$59.11M |
| Net Cash Flow From Investing Activities | $31.29M |
| Net Cash Flow From Investing Activities, Continuing | $31.29M |
| Net Cash Flow From Financing Activities | $56.16M |
| Net Cash Flow From Financing Activities, Continuing | $56.15M |
| Exchange Gains/Losses | $17.00K |
| Net Cash Flow | $28.36M |
| Net Cash Flow, Continuing | $28.34M |
| Comprehensive Income/Loss | -$194.61M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$194.61M |
| Other Comprehensive Income/Loss | -$70.02M |